Safety and Efficacy Data: The CheckMate 9ER Trial

Experts share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma and comment on emerging data in the field.

In an OncView™ program, David H. Aggen, MD, PhD, Robert S. Alter, MD, Arnab Basu, MD, MPH, FACP, Mehmet Asim Bilen, MD, and Chung-Han Lee, MD, MPH, offer their expert insights for the treatment of RCC.

Thought leaders Daniel P. Petrylak, MD; Benjamin H. Lowentritt, MD; Alan H. Bryce, MD; and Tanya Dorff, MD, joined CancerNetwork® following the 2022 Genitourinary Cancers Symposium to discuss highlights of the meeting in a game show–style production.

Lead author, Quirin Zangl, MD, spoke with CancerNetwork about research published in the journal ONCOLOGY focusing on the importance comprehensive geriatric assessment tools for patients with genitourinary carcinomas.

Efficacy of adjuvant mitotane for patients with adrenocortical carcinoma following surgery was presented at 2022 ASCO GU.

At 2022 ASCO GU, early trial results show promise for fluorodeoxyglucose and sodium fluoride PET/CT prognostic ability to predict survival in patients with metastatic genitourinary malignancies treated with cabozantinib plus PD-1/CTLA-3 inhibition.